Na^+/H^+ Exchange Inhibitor SM-20220 Improves Endothelial Dysfunction Induced by Ischemia-Reperfusion
スポンサーリンク
概要
- 論文の詳細を見る
Endothelial cells play an important role in the physiologic homeostasis of the cerebral circulation. Previously, we showed that the Na+/H + exchanger (NHE) inhibitor SM-20220 (N-(aminoiminomethyl)-1-methyl-1H-indole-2-carboxamide methanesulfonate) improved ischemic brain injury. In this study, we investigated the effect of SM-20220 on cerebrovascular dysfunction after ischemia-reperfusion, focusing on the kinds of dysfunction that involved endothelial function. In cultured bovine brain microvascular endothelial cells (BBMCs), the IC50 value for the NHE activity of SM-20220 was 4 × 10−8 M. SM-20220 also reduced the cell injury induced by hypoxia/aglycemia-reoxygenation in BBMCs, with statistical significance at 10−7 M (P<0.05). Next, the effect of SM-20220 on disruption of the blood-brain barrier and cerebral blood flow were evaluated using transient middle cerebral artery (MCA) occlusion models. Intravenous infusion of SM-20220 (0.4 mg/kg per hour for 1 h) attenuated the extravasation of Evans blue, a blood-brain barrier disruption indicator, into cerebral tissue on the day after transient ischemia (P<0.05). The occlusion of the MCA decreased the cerebral blood flow in the MCA territory by about 20%, and only about 45% of the preischemic value was recovered at 1-h reperfusion. A bolus injection of SM-20220 (1 mg/kg, i.v.) improved the postischemic hypoperfusion by about 75%, without causing changes in the systemic blood pressure. These results indicate that the protective effect of NHE inhibitor on ischemic brain injury may be at least partially mediated by the prevention of endothelial dysfunction.
- 社団法人 日本薬理学会の論文
- 2001-03-01
著者
-
MATSUI Kouhei
Graduate School of Pharmaceutical Sciences, Osaka University
-
Ohashi N
Discovery Research Laboratories I Research Center Sumitomo Pharmaceuticals Co. Ltd
-
Ohashi N
Sumitomo Pharmaceuticals Research Division
-
Horikawa N
Sumitomo Pharmaceuticals Research Division
-
Matsui Kazuki
Sumitomo Pharmaceuticals Research Division
-
HORIKAWA Naotsugu
Sumitomo Pharmaceuticals Research Division
-
KURIBAYASHI Yoshikazu
Sumitomo Pharmaceuticals Research Division
-
ITOH Natsuko
Sumitomo Pharmaceuticals Research Division
-
NISHIOKA Mizue
Sumitomo Pharmaceuticals Research Division
-
KAWAMURA Nobuko
Sumitomo Pharmaceuticals Research Division
-
OHASHI Naohito
Sumitomo Pharmaceuticals Research Division
関連論文
- Sesquiterpene Aminoquinones, from a Marine Sponge, Induce Erythroid Differentiation in Human Chronic Myelogenous Leukemia, K562 Cells
- Asymmetric Synthesis of SM-9164, a Biologically Active Enantiomer of Antifungal Agent SM-8668
- Sterospecific Actolysis of threo- and erythro-2-Aryl-2-[1-methylthio)ethl]oxiranes
- Synthesis and Biological Activity of N-(Aminoiminomethyl)-1H-indole Carboxamide Derivatives as Na^+/H^+ Exchanger Inhibitors
- Protective Effect of SM-19712, a Novel and Potent Endothelin Converting Enzyme Inhibitor, on Ischemic Acute Renal Failure in Rats
- Increase in Vascular Sensitivity to Angiotensin II and Norepinephrine after Four - Day Infusion of 0.3M Sodium Chloride in Conscious Kininogen - Deficient Brown Norway Katholiek Rats
- Pharmacological Characterization of a Novel Sulfonylureid-Pyrazole Derivative, SM-19712, a Potent Nonpeptidic Inhibitor of Endothelin Converting Enzyme
- Relationship between the Neuroprotective Effect of Na^+/H^+ Exchanger Inhibitor SM-20220 and the Timing of Its Administration in a Transient Middle Cerebral Artery Occlusion Model of Rats
- Na^+/H^+ Exchange Inhibitor SM-20220 Improves Endothelial Dysfunction Induced by Ischemia-Reperfusion